These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14701987)

  • 1. Dynamic magnetic resonance tomography and proton magnetic resonance spectroscopy of prostate cancers in rats treated by radiotherapy.
    Kiessling F; Huber PE; Grobholz R; Heilmann M; Meding J; Lichy MP; Fink C; Krix M; Peschke P; Schlemmer HP
    Invest Radiol; 2004 Jan; 39(1):34-44. PubMed ID: 14701987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hemodynamic and metabolic characterization of orthotopic rat prostate carcinomas using dynamic MRI and proton magnetic resonance spectroscopy].
    Kiessling F; Lichy M; Grobholz R; Heilmann M; Huber PE; Meding J; Peschke P; Kauczor HU; Schlemmer HP
    Radiologe; 2003 Jun; 43(6):489-94. PubMed ID: 12827264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [1H magnetic resonance spectroscopy of the prostate].
    Mueller-Lisse UG; Scherr M
    Radiologe; 2003 Jun; 43(6):481-8. PubMed ID: 12827263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer.
    van Dorsten FA; van der Graaf M; Engelbrecht MR; van Leenders GJ; Verhofstad A; Rijpkema M; de la Rosette JJ; Barentsz JO; Heerschap A
    J Magn Reson Imaging; 2004 Aug; 20(2):279-87. PubMed ID: 15269954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of proton magnetic resonance spectroscopy (1H-MRS) in the diagnosis of localized prostate cancer.
    Saito K; Kaminaga T; Muto S; Ide H; Nishio K; Kamiyama Y; Okada H; Terado Y; Furui S; Horie S
    Anticancer Res; 2008; 28(3B):1899-904. PubMed ID: 18630478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vivo metabolic characterization of healthy prostate and orthotopic prostate cancer in rats using proton magnetic resonance spectroscopy at 4.7 T.
    Walker P; Provent P; Tizon X; Créhange G; Duchamp O; Brunotte F; Genne P
    Acta Radiol; 2013 Feb; 54(1):121-6. PubMed ID: 23081956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation of prostate cancer from normal prostate tissue in an animal model: conventional MRI and dynamic contrast-enhanced MRI.
    Gemeinhardt O; Lüdemann L; Prochnow D; Abramjuk C; Taupitz M; Hamm B; Beyersdorff D
    Rofo; 2005 Jul; 177(7):935-9. PubMed ID: 15973594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic resonance spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magnetic resonance (DCE-MRI): pattern changes from inflammation to prostate cancer.
    Sciarra A; Panebianco V; Ciccariello M; Salciccia S; Lisi D; Osimani M; Alfarone A; Gentilucci A; Parente U; Passariello R; Gentile V
    Cancer Invest; 2010 May; 28(4):424-32. PubMed ID: 20073578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1H-MRSI of prostate cancer: the relationship between metabolite ratio and tumor proliferation.
    Wang XZ; Wang B; Gao ZQ; Liu JG; Liu ZQ; Niu QL; Sun ZK; Yuan YX
    Eur J Radiol; 2010 Feb; 73(2):345-51. PubMed ID: 19070978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of prostate carcinomas with T1-weighted dynamic contrast-enhanced MRI. Value of two-compartment model].
    Kiessling F; Lichy M; Grobholz R; Farhan N; Heilmann M; Michel MS; Trojan L; Werner A; Rabe J; Delorme S; Kauczor HU; Schlemmer HP
    Radiologe; 2003 Jun; 43(6):474-80. PubMed ID: 12827262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience.
    Hsieh TJ; Li CW; Chuang HY; Liu GC; Wang CK
    J Comput Assist Tomogr; 2008; 32(6):987-94. PubMed ID: 19204465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton MR spectroscopy of the prostate.
    Mueller-Lisse UG; Scherr MK
    Eur J Radiol; 2007 Sep; 63(3):351-60. PubMed ID: 17709223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrast/Noise ratio on conventional MRI and choline/creatine ratio on proton MRI spectroscopy accurately discriminate low-grade from high-grade cerebral gliomas.
    Fayed N; Morales H; Modrego PJ; Pina MA
    Acad Radiol; 2006 Jun; 13(6):728-37. PubMed ID: 16679275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.
    Haider MA; Chung P; Sweet J; Toi A; Jhaveri K; Ménard C; Warde P; Trachtenberg J; Lockwood G; Milosevic M
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):425-30. PubMed ID: 17881141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton magnetic resonance spectroscopic findings of cerebral fat embolism induced by triolein emulsion in cats.
    Baik SK; Kim YW; Kim HJ; Lee JW; Cho BM; Kim DH; Choi SH; Lee SH; Chang KH
    Acta Radiol; 2008 Dec; 49(10):1174-81. PubMed ID: 19031181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
    Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
    BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI spectroscopy in screening of prostate cancer.
    Goeb K; Engehausen DG; Krause FS; Hollenbach HP; Niedobitek G; Buettner M; Frangou P; Engelhard K
    Anticancer Res; 2007; 27(1B):687-93. PubMed ID: 17348461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of tumor histology to dynamic contrast enhanced magnetic resonance imaging-based physiological estimates.
    Aref M; Chaudhari AR; Bailey KL; Aref S; Wiener EC
    Magn Reson Imaging; 2008 Nov; 26(9):1279-93. PubMed ID: 18487033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of nuclear magnetic resonance spectroscopy (MRS) in cancer diagnosis and treatment: 31P, 23Na, and 1H MRS studies of three models of pancreatic cancer.
    Kaplan O; Kushnir T; Askenazy N; Knubovets T; Navon G
    Cancer Res; 1997 Apr; 57(8):1452-9. PubMed ID: 9108445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.